| Asset |
Phase |
Rationale |
| SWT-001 |
1 |
Combination clinically validated for sleep benefits. Target also has clinical validation for AD psychosis
Predicted opportunity for disease modification 13 week GLP Tox in rodent and dog completed Human PK and PD data available (Ph1 SAD) |
|
SWT-002 |
Clinical candidate |
Clinically validated for sleep benefits (as above)
Non GLP rodent and non-rodent tox. completed |
| SWT-003 |
Pre-clinical |
Target clinically validated for anxiolytic activity. Pre-clinical in vivo data package demonstrates SWS consolidation, antipsychotic and analgesic effects.
4-day rat pilot tox completed on lead molecule |